Cryo-EM structure of active GPR65 leadXpro has just elucidated the world’s first structure of a proton-sensing GPCR target.

Discover our technology Discover our Technology

Accelerating projects from gene to lead

Explore partnering options Discover our Technology

Uniting experts in structural biology

Meet our team Discover our Technology

ABOUT leadXpro

Welcome to leadXpro, where we specialize in structure-based drug discovery for membrane proteins. Our team of experts brings together knowledge in membrane protein science, pioneering technologies in structural biology, and expertise in ligand design and characterization to help our clients develop new and innovative therapies.

At leadXpro, we are dedicated to helping our clients unlock the potential of membrane proteins to improve human health. Our research covers a range of membrane proteins, including GPCRs, ion channels, transporters, and enzymes, giving us a unique and comprehensive perspective on the drug discovery target space.

But we don’t just stop at research. As a contract research partner, we offer a variety of services and partnership models to a growing number of pharmaceutical, biotech, and academic partners. Our flexible approach allows us to work with clients at every stage of their drug discovery project, from hit finding and validation, to structure-based optimization of preclinical compounds.

So if you’re looking to make a breakthrough in drug discovery, look no further than leadXpro. Contact us today to learn more about how we can help you achieve your goals.

See our technology platform

ABOUT leadXpro

So if you’re looking to make a breakthrough in drug discovery, look no further than leadXpro. Contact us today to learn more about how we can help you achieve your goals.

See our technology platform

WORK WITH US

leadXpro is the partner of choice for membrane protein structural biology and can boost any drug discovery project from gene to lead.

Why choose us

WORK WITH US

leadXpro is the partner of choice for membrane protein structural biology and can boost any drug discovery project from gene to lead.

Why choose us

THERAPEUTICS

Using its unique technology platform, leadXpro is developing proprietary preclinical compounds with high efficacy and specificity.

See our pipeline

THERAPEUTICS

Using its unique technology platform, leadXpro is developing proprietary preclinical compounds with high efficacy and specificity.

See our pipeline

CLIMBING THE STEEPEST MOUNTAINS

leadXpro’s team of experts provides the knowledge and technologies to meet the challenges of membrane proteins.

Meet our team

CLIMBING THE STEEPEST MOUNTAINS

leadXpro’s team of experts provides the knowledge and technologies to meet the challenges of membrane proteins.

Meet our team

leadXpro Timeline

Latest updates about leadXpro

September 3, 2024

leadXpro and Alipheron are combining their cutting-edge technologies to bring a new level of innovation to early drug discovery.

By applying intelligent algorithms to detect new drugs in trillions of molecules By using high-tech Cryo-EM to elucidate structures of membrane bound proteins By accelerating structure-based lead discovery to address unmet medical needs

August 20, 2024

Cumulus Oncology and leadXpro Achieve Critical Milestone in GPR68 Drug Discovery Project

Edinburgh, Scotland, and Villigen, Switzerland, 13 August 2024 – Cumulus Oncology, Europe’s first oncology-focused biotech creation company, announces that, in partnership with its collaborator leadXpro (LXP), key milestones have been achieved in their protein structure driven GPR68 drug discovery project. As a result, Cumulus has licensed the small molecule compounds and associated IP created during […]

May 29, 2024

Golgi Neurosciences and leadXpro announce collaboration on GPR65 modulators

Milan, Italy, and Villigen, Switzerland 29th May 2024. Today, we are happy to announce our partnership with Golgi Neurosciences, a pioneering company-creator boutique dedicated to developing therapies for neurodegenerative diseases.Together, we created significant progress with different classes of positive and negative modulators of GPR65, a proton-sensing G protein–coupled receptor (GPCR). This receptor is involved in […]